{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:03:11Z","timestamp":1791820991871,"version":"4.3.4"},"reference-count":105,"publisher":"Georg Thieme Verlag KG","issue":"02","funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"crossref","award":["5\/8\/5\/45\/multicentric study\/2019\/ECD-I"],"award-info":[{"award-number":["5\/8\/5\/45\/multicentric study\/2019\/ECD-I"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Liver Dis"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:p>Drug-induced liver injury (DILI) is a rare but severe adverse drug reaction seen in pharmacotherapy and a major cause of postmarketing drug withdrawals. Advances in genome-wide studies indicate that genetic and epigenetic diversity can lead to inter-individual differences in drug response and toxicity. It is necessary to identify how the genetic variations, in the presence of environmental factors, can contribute to development and progression of DILI. Studies on microRNA, histone modification, DNA methylation, and single nucleotide polymorphisms related to DILI were retrieved from databases and were analyzed for the current research and updated to develop this narrative review. We have compiled some of the major genetic, epigenetic, and pharmacogenetic factors leading to DILI. Many validated genetic risk factors of DILI, such as variants of drug-metabolizing enzymes, HLA alleles, and some transporters were identified. In conclusion, these studies provide useful information in risk alleles identification and on implementation of personalized medicine.<\/jats:p>","DOI":"10.1055\/a-2097-0531","type":"journal-article","created":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T23:17:56Z","timestamp":1684970276000},"page":"163-175","source":"Crossref","is-referenced-by-count":12,"title":["Genetic and Epigenetic Basis of Drug-Induced Liver Injury"],"prefix":"10.1055","volume":"43","author":[{"given":"Snigdha","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.V.S.N. Kiran","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Pradeep","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sojit","family":"Tomo","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dharamveer","family":"Yadav","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praveen","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahadev","family":"Rao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences, Manipal, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mithu","family":"Banerjee","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2023,7,5]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"735260","DOI":"10.3389\/fphar.2021.735260","article-title":"Research progress of pharmacogenomics in drug-induced liver injury","volume":"12","author":"Q Shao","year":"2021","journal-title":"Front Pharmacol"},{"issue":"01","key":"ref2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cld.2019.08.003","article-title":"Genetic predisposition to drug-induced liver injury","volume":"24","author":"C Stephens","year":"2020","journal-title":"Clin Liver Dis"},{"issue":"01","key":"ref3","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.mayocp.2013.09.016","article-title":"Drug-induced liver injury","volume":"89","author":"M D Leise","year":"2014","journal-title":"Mayo Clin Proc"},{"issue":"02","key":"ref4","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1042\/CS20171260","article-title":"Sex dependant differences in inflammatory responses during liver regeneration in a murine model of Acute Liver Injury","volume":"132","author":"D Bizzaro","year":"2018","journal-title":"Clin Sci"},{"issue":"05","key":"ref5","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1042\/CS20171313","article-title":"Liver inflammation and regeneration in drug-induced liver injury: sex matters!","volume":"132","author":"S Sutti","year":"2018","journal-title":"Clin Sci (Lond)"},{"issue":"10","key":"ref6","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1007\/s00204-020-02885-1","article-title":"Drug induced liver injury: an update","volume":"94","author":"M Garcia-Cortes","year":"2020","journal-title":"Arch Toxicol"},{"issue":"03","key":"ref7","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3350\/cmh.2012.18.3.249","article-title":"Drug-induced liver injury: present and future","volume":"18","author":"K T Suk","year":"2012","journal-title":"Clin Mol Hepatol"},{"issue":"06","key":"ref8","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1136\/gutjnl-2016-313369","article-title":"Drug-induced liver injury: recent advances in diagnosis and risk assessment","volume":"66","author":"G A Kullak-Ublick","year":"2017","journal-title":"Gut"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.3389\/fphar.2019.01667","article-title":"Molecular biomarkers in drug-induced liver injury: challenges and future perspectives","volume":"10","author":"S Fu","year":"2020","journal-title":"Front Pharmacol"},{"issue":"01","key":"ref10","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2165\/00002018-200932010-00005","article-title":"Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct","volume":"32","author":"R J Fontana","year":"2009","journal-title":"Drug Saf"},{"issue":"03","key":"ref11","doi-asserted-by":"crossref","first-page":"390","DOI":"10.3390\/antiox10030390","article-title":"Oxidative stress in drug-induced liver injury (DILI): from mechanisms to biomarkers for use in clinical practice","volume":"10","author":"M Villanueva-Paz","year":"2021","journal-title":"Antioxidants"},{"issue":"05","key":"ref12","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S0016-5085(99)70404-X","article-title":"HLA association of amoxicillin-clavulanate\u2013induced hepatitis","volume":"117","author":"M L Hautekeete","year":"1999","journal-title":"Gastroenterology"},{"issue":"08","key":"ref13","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/ng.632","article-title":"A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury","volume":"42","author":"J B Singer","year":"2010","journal-title":"Nat Genet"},{"issue":"07","key":"ref14","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/ng.379","article-title":"HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin","volume":"41","author":"A K Daly","year":"2009","journal-title":"Nat Genet"},{"issue":"03","key":"ref15","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/sj.tpj.6500458","article-title":"Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis","volume":"8","author":"A Kindmark","year":"2008","journal-title":"Pharmacogenomics J"},{"issue":"06","key":"ref16","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.jhep.2018.08.004","article-title":"The role of HLA-A*33:01 in patients with cholestatic hepatitis attributed to terbinafine","volume":"69","author":"R J Fontana","year":"2018","journal-title":"J Hepatol"},{"issue":"01","key":"ref17","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jhep.2017.03.010","article-title":"Minocycline hepatotoxicity: clinical characterization and identification of HLA-B*35:02 as a risk factor","volume":"67","author":"T J Urban","year":"2017","journal-title":"J Hepatol"},{"issue":"06","key":"ref18","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/apm.12683","article-title":"CYP1A1m1 and CYP2C9*2 and *3 polymorphism and risk to develop ARV-associated hepatotoxicity and its severity","volume":"125","author":"H Singh","year":"2017","journal-title":"APMIS"},{"issue":"01","key":"ref19","first-page":"109","article-title":"The effect of CYP1A2 gene polymorphism on the metabolism of theophylline","volume":"15","author":"S Xiong","year":"2018","journal-title":"Exp Ther Med"},{"issue":"08","key":"ref20","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s00228-020-02872-6","article-title":"Influence of CYP2C9 and CYP2A6 on plasma concentrations of valproic acid: a meta-analysis","volume":"76","author":"H Y Yoon","year":"2020","journal-title":"Eur J Clin Pharmacol"},{"issue":"02","key":"ref21","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/bcpt.12776","article-title":"Associations of CYP2C9 and CYP2A6 polymorphisms with the concentrations of valproate and its hepatotoxin metabolites and valproate-induced hepatotoxicity","volume":"121","author":"M Zhao","year":"2017","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"06","key":"ref22","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/tpj.2011.34","article-title":"High plasma efavirenz level and CYP2B6*6 are associated with efavirenz-based HAART-induced liver injury in the treatment of na\u00efve HIV patients from Ethiopia: a prospective cohort study","volume":"12","author":"G Yimer","year":"2012","journal-title":"Pharmacogenomics J"},{"issue":"02","key":"ref23","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/tpj.2015.70","article-title":"Interethnic variation of CYP2C19 alleles, \u2018predicted\u2019 phenotypes and \u2018measured\u2019 metabolic phenotypes across world populations","volume":"16","author":"I Fricke-Galindo","year":"2016","journal-title":"Pharmacogenomics J"},{"issue":"03","key":"ref24","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1001\/jamapsychiatry.2020.3643","article-title":"Association of CYP2C19 and CYP2D6 poor and intermediate metabolizer status with antidepressant and antipsychotic exposure: a systematic review and meta-analysis","volume":"78","author":"F Milosavljevi\u0107","year":"2021","journal-title":"JAMA Psychiatry"},{"issue":"04","key":"ref25","doi-asserted-by":"crossref","first-page":"335","DOI":"10.4103\/IJPSYM.IJPSYM_83_18","article-title":"A prospective study to evaluate the effect of CYP2D6 polymorphism on plasma level of risperidone and its metabolite in north Indian patients with schizophrenia","volume":"40","author":"B S Chavan","year":"2018","journal-title":"Indian J Psychol Med"},{"issue":"01","key":"ref26","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41398-020-01129-1","article-title":"Meta-analysis of probability estimates of worldwide variation of CYP2D6 and CYP2C19","volume":"11","author":"A B Koopmans","year":"2021","journal-title":"Transl Psychiatry"},{"issue":"07","key":"ref27","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1111\/liv.14896","article-title":"Incidence and risk factors of anti-tuberculosis drug induced liver injury (DILI): large cohort study involving 4652 Chinese adult tuberculosis patients","volume":"41","author":"F Jiang","year":"2021","journal-title":"Liver Int"},{"issue":"12","key":"ref28","first-page":"1258","article-title":"Association between polymorphism of NUDT15 gene and hepatotoxicity induced by 6-MP in children with acute lymphoblastic leukemia [in Chinese]","volume":"38","author":"X Wang","year":"2021","journal-title":"Zhonghua Yi Xue Yi Chuan Xue Za Zhi"},{"issue":"03","key":"ref29","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/01.ftd.0000211823.80854.db","article-title":"Sequence-based CYP2D6 genotyping in the Korean population","volume":"28","author":"S Y Lee","year":"2006","journal-title":"Ther Drug Monit"},{"issue":"02","key":"ref30","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/PL00005334","article-title":"Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4","volume":"359","author":"J Fang","year":"1999","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"04","key":"ref31","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1053\/jhep.2003.50144","article-title":"Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis","volume":"37","author":"Y S Huang","year":"2003","journal-title":"Hepatology"},{"issue":"07","key":"ref32","doi-asserted-by":"crossref","first-page":"935","DOI":"10.3390\/pharmaceutics13070935","article-title":"Review of pharmacokinetics and pharmacogenetics in atypical long-acting injectable antipsychotics","volume":"13","author":"F J Toja-Camba","year":"2021","journal-title":"Pharmaceutics"},{"issue":"08","key":"ref33","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s00228-006-0165-4","article-title":"Associations between CYP2E1 promoter polymorphisms and plasma 1,3-dimethyluric acid\/theophylline ratios","volume":"62","author":"Y Yoon","year":"2006","journal-title":"Eur J Clin Pharmacol"},{"issue":"01","key":"ref34","doi-asserted-by":"crossref","first-page":"33","DOI":"10.55705\/cmbr.2021.138880.1003","article-title":"Relevance of genetic polymorphisms of the human cytochrome P450 3A4 in rivaroxaban-treated patients","volume":"1","author":"M F Ercisli","year":"2021","journal-title":"Cell Mol Biomed Rep"},{"issue":"04","key":"ref35","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1177\/0394632017733638","article-title":"Association of UGT2B7 polymorphisms with risk of induced liver injury by anti-tuberculosis drugs in Chinese Han","volume":"30","author":"G Chen","year":"2017","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"03","key":"ref36","first-page":"201","article-title":"Relationship between the polymorphisms of UGT1A6 genes and anti-tuberculosis drug induced hepatic-injury [in Chinese]","volume":"19","author":"J-Q Hao","year":"2011","journal-title":"Chin J Hepatol"},{"issue":"02","key":"ref37","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1080\/17425255.2021.1854726","article-title":"Genetic risk factors in the development of idiosyncratic drug-induced liver injury","volume":"17","author":"C Stephens","year":"2021","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"03","key":"ref38","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/clpt.2012.107","article-title":"Predictive genetic testing for drug-induced liver injury: considerations of clinical utility","volume":"92","author":"A Alfirevic","year":"2012","journal-title":"Clin Pharmacol Ther"},{"issue":"01","key":"ref39","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1053\/j.gastro.2006.11.023","article-title":"Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes","volume":"132","author":"A K Daly","year":"2007","journal-title":"Gastroenterology"},{"issue":"02","key":"ref40","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1093\/toxsci\/49.2.156","article-title":"Concise review of the glutathione S-transferases and their significance to toxicology","volume":"49","author":"D L Eaton","year":"1999","journal-title":"Toxicol Sci"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.toxlet.2020.11.007","article-title":"Human variability in glutathione-S-transferase activities, tissue distribution and major polymorphic variants: meta-analysis and implication for chemical risk assessment","volume":"337","author":"F M Buratti","year":"2021","journal-title":"Toxicol Lett"},{"issue":"06","key":"ref42","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/j.1478-3231.2008.01700.x","article-title":"Influence of glutathione S-transferase M1 and T1 homozygous null mutations on the risk of antituberculosis drug-induced hepatotoxicity in a Caucasian population","volume":"28","author":"V Leiro","year":"2008","journal-title":"Liver Int"},{"issue":"04","key":"ref43","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1067\/mcp.2000.104944","article-title":"Combined glutathione-S-transferase M1 and T1 genetic polymorphism and tacrine hepatotoxicity","volume":"67","author":"T Simon","year":"2000","journal-title":"Clin Pharmacol Ther"},{"issue":"05","key":"ref44","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0009-9236(03)00014-6","article-title":"A study to survey susceptible genetic factors responsible for troglitazone-associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus","volume":"73","author":"I Watanabe","year":"2003","journal-title":"Clin Pharmacol Ther"},{"issue":"03","key":"ref45","doi-asserted-by":"crossref","first-page":"300","DOI":"10.2353\/jmoldx.2010.090076","article-title":"Simultaneous genotyping of GSTT1 and GSTM1 null polymorphisms by melting curve analysis in presence of SYBR Green I","volume":"12","author":"F Mar\u00edn","year":"2010","journal-title":"J Mol Diagn"},{"issue":"10","key":"ref46","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.5588\/ijtld.15.0310","article-title":"NAT2 slow acetylator associated with anti-tuberculosis drug-induced liver injury in Thai patients","volume":"20","author":"S Wattanapokayakit","year":"2016","journal-title":"Int J Tuberc Lung Dis"},{"issue":"10","key":"ref47","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1021\/acs.chemrestox.2c00175","article-title":"Nitroreduction: a critical metabolic pathway for drugs, environmental pollutants, and explosives","volume":"35","author":"T M Penning","year":"2022","journal-title":"Chem Res Toxicol"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0027-5107(02)00153-7","article-title":"Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis","volume":"506\u2013507","author":"D W Hein","year":"2002","journal-title":"Mutat Res"},{"issue":"06","key":"ref49","doi-asserted-by":"crossref","first-page":"924","DOI":"10.4103\/ijmr.IJMR_684_14","article-title":"Genetic polymorphisms of N-acetyltransferase 2 & susceptibility to antituberculosis drug-induced hepatotoxicity","volume":"144","author":"S K Sharma","year":"2016","journal-title":"Indian J Med Res"},{"key":"ref50","first-page":"91","volume-title":"Pharmacogenetics polymorphisms in xenobiotic metabolism","author":"F J Gonzalez","year":"1999"},{"issue":"05","key":"ref51","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1007\/s11033-012-2433-y","article-title":"Slow N-acetyltransferase 2 genotype contributes to anti-tuberculosis drug-induced hepatotoxicity: a meta-analysis","volume":"40","author":"H Du","year":"2013","journal-title":"Mol Biol Rep"},{"issue":"12","key":"ref52","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1111\/bcp.13722","article-title":"The association between the NAT2 genetic polymorphisms and risk of DILI during anti-TB treatment: a systematic review and meta-analysis","volume":"84","author":"M Zhang","year":"2018","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"ref53","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1164\/rccm.202103-0564OC","article-title":"A rapid pharmacogenomic assay to detect NAT2 polymorphisms and guide isoniazid dosing for tuberculosis treatment","volume":"204","author":"R Verma","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"ref54","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1007\/s00109-017-1570-0","article-title":"miR-27b-3p, miR-181a-1-3p, and miR-326-5p are involved in the inhibition of macrophage activation in chronic liver injury","volume":"95","author":"W Li","year":"2017","journal-title":"J Mol Med (Berl)"},{"issue":"04","key":"ref55","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00228-016-2183-1","article-title":"Role of miRNA and its potential as a novel diagnostic biomarker in drug-induced liver injury","volume":"73","author":"S Sanjay","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1146\/annurev-pharmtox-030220-015007","article-title":"Models of idiosyncratic drug-induced liver injury","volume":"61","author":"T Yokoi","year":"2021","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"03","key":"ref57","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1080\/10590501.2019.1639481","article-title":"Regulation of cytochrome P450 expression by microRNAs and long noncoding RNAs: Epigenetic mechanisms in environmental toxicology and carcinogenesis","volume":"37","author":"D Li","year":"2019","journal-title":"J Environ Sci Health Part C Environ Carcinog Ecotoxicol Rev"},{"issue":"02","key":"ref58","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/bcpt.13313","article-title":"CYP2E1 and miRNA-378a-3p contribute to acetaminophen- or tripterygium glycosides-induced hepatotoxicity","volume":"126","author":"K Chen","year":"2020","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3389\/fmed.2020.00007","article-title":"Critical role of microRNA-21 in the pathogenesis of liver diseases","volume":"7","author":"T Zhang","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"734090","DOI":"10.3389\/fphar.2021.734090","article-title":"The LAC score indicates significant fibrosis in patients with chronic drug-induced liver injury: a large biopsy-based study","volume":"12","author":"Z B Li","year":"2021","journal-title":"Front Pharmacol"},{"issue":"05","key":"ref61","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/j.jcmgh.2021.07.011","article-title":"Protective role of microRNA-31 in acetaminophen-induced liver injury: a negative regulator of c-Jun N-terminal kinase (JNK) signaling pathway","volume":"12","author":"J Zheng","year":"2021","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"02","key":"ref62","first-page":"229","article-title":"A novel MicroRNA signature for cholestatic drugs in human hepatocytes and its translation into novel circulating biomarkers for drug-induced liver injury patients","volume":"173","author":"M L\u00f3pez-Riera","year":"2020","journal-title":"Toxicol Sci"},{"issue":"11","key":"ref63","doi-asserted-by":"crossref","first-page":"4402","DOI":"10.1073\/pnas.0813371106","article-title":"Circulating microRNAs, potential biomarkers for drug-induced liver injury","volume":"106","author":"K Wang","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"02","key":"ref64","doi-asserted-by":"publisher","DOI":"10.5812\/jjnpp.65678","article-title":"Circulating miR-122 and miR-192 as specific and sensitive biomarkers for drug-induced liver injury with acetaminophen in rats","volume":"14","author":"P Jarsiah","year":"2019","journal-title":"Jundishapur J Nat Pharm Prod"},{"issue":"09","key":"ref65","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1177\/0960327121997975","article-title":"Altered expressions of circulating microRNAs 122 and 192 during antitubercular drug induced liver injury indicating their role as potential biomarkers","volume":"40","author":"S Bakshi","year":"2021","journal-title":"Hum Exp Toxicol"},{"issue":"49","key":"ref66","doi-asserted-by":"crossref","first-page":"e13478","DOI":"10.1097\/MD.0000000000013478","article-title":"The diagnostic role of miR-122 in drug-induced liver injury: a systematic review and meta-analysis","volume":"97","author":"Y Liu","year":"2018","journal-title":"Medicine (Baltimore)"},{"issue":"02","key":"ref67","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1007\/s11010-020-03988-0","article-title":"MiR-122-5p knockdown protects against APAP-mediated liver injury through up-regulating NDRG3","volume":"476","author":"Z Yang","year":"2021","journal-title":"Mol Cell Biochem"},{"issue":"02","key":"ref68","doi-asserted-by":"crossref","first-page":"024108","DOI":"10.1063\/5.0085078","article-title":"Microfluidic system for near-patient extraction and detection of miR-122 microRNA biomarker for drug-induced liver injury diagnostics","volume":"16","author":"M Kersaudy-Kerhoas","year":"2022","journal-title":"Biomicrofluidics"},{"issue":"05","key":"ref69","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1111\/liv.13312","article-title":"Profiles of miRNAs in serum in severe acute drug induced liver injury and their prognostic significance","volume":"37","author":"M W Russo","year":"2017","journal-title":"Liver Int"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"114489","DOI":"10.1016\/j.jep.2021.114489","article-title":"Role of MicroRNA-155 in triptolide-induced hepatotoxicity via the Nrf2-dependent pathway","volume":"281","author":"Y Li","year":"2021","journal-title":"J Ethnopharmacol"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.intimp.2016.09.011","article-title":"Fine-tuning the expression of microRNA-155 controls acetaminophen-induced liver inflammation","volume":"40","author":"K Yuan","year":"2016","journal-title":"Int Immunopharmacol"},{"issue":"04","key":"ref72","doi-asserted-by":"crossref","first-page":"714","DOI":"10.3892\/mmr.2021.12353","article-title":"Functional role of miR\u2013155 in physiological and pathological processes of liver injury (Review)","volume":"24","author":"X Feng","year":"2021","journal-title":"Mol Med Rep"},{"issue":"02","key":"ref73","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/hep.29833","article-title":"Expression of microRNA-155 in inflammatory cells modulates liver injury","volume":"68","author":"D Blaya","year":"2018","journal-title":"Hepatology"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12575-018-0082-9","article-title":"microRNA regulation in estrogen receptor-positive breast cancer and endocrine therapy","volume":"20","author":"E W Howard","year":"2018","journal-title":"Biol Proced Online"},{"issue":"04","key":"ref75","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1136\/gutjnl-2020-322526","article-title":"MicroRNAs as regulators, biomarkers and therapeutic targets in liver diseases","volume":"70","author":"X Wang","year":"2021","journal-title":"Gut"},{"key":"ref76","doi-asserted-by":"crossref","first-page":"860661","DOI":"10.3389\/fimmu.2022.860661","article-title":"MiR-223 as a regulator and therapeutic target in liver diseases","volume":"13","author":"J Gu","year":"2022","journal-title":"Front Immunol"},{"issue":"09","key":"ref77","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-018-0153-7","article-title":"Role of miR-223 in the pathophysiology of liver diseases","volume":"50","author":"D Ye","year":"2018","journal-title":"Exp Mol Med"},{"key":"ref78","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.scitotenv.2018.07.109","article-title":"Modulation of mitochondrial functions by xenobiotic-induced microRNA: from environmental sentinel organisms to mammals","volume":"645","author":"M A Burgos-Aceves","year":"2018","journal-title":"Sci Total Environ"},{"issue":"03","key":"ref79","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.3390\/ijms22031492","article-title":"From liver cirrhosis to cancer: the role of micro-RNAs in hepatocarcinogenesis","volume":"22","author":"R Mohr","year":"2021","journal-title":"Int J Mol Sci"},{"key":"ref80","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.tox.2014.02.011","article-title":"Involvement of miRNAs in the early phase of halothane-induced liver injury","volume":"319","author":"S Endo","year":"2014","journal-title":"Toxicology"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"153133","DOI":"10.1016\/j.tox.2022.153133","article-title":"Identification of miRNAs involved in liver injury induced by chronic exposure to cadmium","volume":"469","author":"X Jiang","year":"2022","journal-title":"Toxicology"},{"issue":"03","key":"ref82","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1089\/aivt.2020.0008","article-title":"Exosomal microRNAs release as a sensitive marker for drug-induced liver injury in vitro","volume":"6","author":"C J Messner","year":"2020","journal-title":"Appl In Vitro Toxicol"},{"issue":"08","key":"ref83","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1111\/bcp.14736","article-title":"MicroRNA-122 and cytokeratin-18 have potential as a biomarkers of drug-induced liver injury in European and African patients on treatment for mycobacterial infection","volume":"87","author":"S AE Rupprechter","year":"2021","journal-title":"Br J Clin Pharmacol"},{"issue":"06","key":"ref84","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jbt.22753","article-title":"Ameliorative effect of betanin on experimental cisplatin-induced liver injury; the novel impact of miRNA-34a on the SIRT1\/PGC-1\u03b1 signaling pathway","volume":"35","author":"I El Shaffei","year":"2021","journal-title":"J Biochem Mol Toxicol"},{"issue":"03","key":"ref86","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.etap.2011.07.001","article-title":"DNA methylation in the rat livers induced by low dosage isoniazid treatment","volume":"32","author":"B Zhang","year":"2011","journal-title":"Environ Toxicol Pharmacol"},{"issue":"01","key":"ref87","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.etap.2013.03.016","article-title":"Methylation of cytochrome p450 2E1 promoter induced by low dosage of isoniazid","volume":"36","author":"L Shen","year":"2013","journal-title":"Environ Toxicol Pharmacol"},{"issue":"05","key":"ref88","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/s41397-020-0160-7","article-title":"A methylation functional detection hepatic cell system validates correlation between DNA methylation and drug-induced liver injury","volume":"20","author":"Y Wei","year":"2020","journal-title":"Pharmacogenomics J"},{"issue":"10","key":"ref89","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1101\/gad.2037511","article-title":"CpG islands and the regulation of transcription","volume":"25","author":"A M Deaton","year":"2011","journal-title":"Genes Dev"},{"issue":"08","key":"ref90","doi-asserted-by":"crossref","first-page":"776","DOI":"10.3390\/ijerph13080776","article-title":"Correlation of CpG island methylation of the cytochrome P450 2E1\/2D6 genes with liver injury induced by anti-tuberculosis drugs: a nested case-control study","volume":"13","author":"J Zhang","year":"2016","journal-title":"Int J Environ Res Public Health"},{"issue":"06","key":"ref91","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1177\/1947601910393957","article-title":"DNA methylation: superior or subordinate in the epigenetic hierarchy?","volume":"2","author":"B Jin","year":"2011","journal-title":"Genes Cancer"},{"key":"ref92","first-page":"e920350","article-title":"Drug-induced liver injury from anti-tuberculosis treatment: a retrospective cohort study","volume":"26","author":"H Zhao","year":"2020","journal-title":"Med Sci Monit"},{"issue":"06","key":"ref93","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.alcohol.2010.06.003","article-title":"Evidence for the role of oxidative stress in the acetylation of histone H3 by ethanol in rat hepatocytes","volume":"44","author":"M Choudhury","year":"2010","journal-title":"Alcohol"},{"key":"ref94","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/HMER.S290542","article-title":"Anti-tuberculosis drug induced hepatotoxicity and associated factors among tuberculosis patients at selected hospitals, Ethiopia","volume":"13","author":"Y Molla","year":"2021","journal-title":"Hepat Med"},{"issue":"03","key":"ref95","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.taap.2007.08.011","article-title":"Epigenetic changes in the rat livers induced by pyrazinamide treatment","volume":"225","author":"V M Kovalenko","year":"2007","journal-title":"Toxicol Appl Pharmacol"},{"issue":"06","key":"ref96","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1002\/cpt.1563","article-title":"Genome-wide analysis of DNA methylation and antituberculosis drug-induced liver injury in the han chinese population","volume":"106","author":"C Huai","year":"2019","journal-title":"Clin Pharmacol Ther"},{"issue":"03","key":"ref97","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.livres.2019.06.001","article-title":"Inhibition of mitochondrial fatty acid oxidation in drug-induced hepatic steatosis","volume":"3","author":"B Fromenty","year":"2019","journal-title":"Liver Res"},{"issue":"02","key":"ref98","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/jcb.240510208","article-title":"4-Quinolones cause a selective loss of mitochondrial DNA from mouse L1210 leukemia cells","volume":"51","author":"J W Lawrence","year":"1993","journal-title":"J Cell Biochem"},{"issue":"05","key":"ref99","first-page":"1178","article-title":"Delayed cytotoxicity and cleavage of mitochondrial DNA in ciprofloxacin-treated mammalian cells","volume":"50","author":"J W Lawrence","year":"1996","journal-title":"Mol Pharmacol"},{"key":"ref100","first-page":"273","article-title":"Mitochondrial, metabolic and genotoxic effects of antiretroviral nucleoside reverse-transcriptase inhibitors","volume":"5","author":"A Igoudjil","year":"2006","journal-title":"Antiinfect Agents"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"110916","DOI":"10.1016\/j.fct.2019.110916","article-title":"Alteration of mitochondrial DNA homeostasis in drug-induced liver injury","volume":"135","author":"B Fromenty","year":"2020","journal-title":"Food Chem Toxicol"},{"issue":"03","key":"ref102","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1080\/15476286.2016.1189071","article-title":"Histone availability as a strategy to control gene expression","volume":"14","author":"F Prado","year":"2017","journal-title":"RNA Biol"},{"key":"ref103","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1615\/CritRevOncog.2015012997","article-title":"Histone deacetylases and mechanisms of regulation of gene expression","volume":"20","author":"H P Chen","year":"2015","journal-title":"Crit Rev Oncog"},{"issue":"03","key":"ref104","first-page":"143","article-title":"Stem cell strategies to evaluate idiosyncratic drug-induced liver injury","volume":"2","author":"W Krueger","year":"2014","journal-title":"J Clin Transl Hepatol"},{"key":"ref105","doi-asserted-by":"crossref","first-page":"837544","DOI":"10.3389\/fphar.2022.837544","article-title":"SIRT6 activator UBCS039 inhibits thioacetamide-induced hepatic injury in vitro and in vivo","volume":"13","author":"F Jiao","year":"2022","journal-title":"Front Pharmacol"},{"issue":"08","key":"ref106","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1089\/dna.2015.3155","article-title":"Differential expression of SWI\/SNF chromatin remodeler subunits brahma and brahma-related gene during drug-induced liver injury and regeneration in mouse model","volume":"35","author":"S Sinha","year":"2016","journal-title":"DNA Cell Biol"}],"container-title":["Seminars in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2097-0531.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T18:02:11Z","timestamp":1690394531000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2097-0531"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":105,"journal-issue":{"issue":"02","published-online":{"date-parts":[[2023,7,14]]},"published-print":{"date-parts":[[2023,5]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2097-0531","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0272-8087","1098-8971"],"issn-type":[{"value":"0272-8087","type":"print"},{"value":"1098-8971","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,5,24]]},"published":{"date-parts":[[2023,5]]}}}